OBLN vs. OSAP, OSA, LLIT, BJDX, RSLS, SINT, NMRD, DYNT, QNRX, and INVO
Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include ProSomnus (OSAP), ProSomnus (OSA), Lianluo Smart (LLIT), Bluejay Diagnostics (BJDX), ReShape Lifesciences (RSLS), Sintx Technologies (SINT), Nemaura Medical (NMRD), Dynatronics (DYNT), Quoin Pharmaceuticals (QNRX), and INVO Bioscience (INVO). These companies are all part of the "medical" sector.
ProSomnus (NASDAQ:OSAP) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment.
Obalon Therapeutics has lower revenue, but higher earnings than ProSomnus.
Obalon Therapeutics received 246 more outperform votes than ProSomnus when rated by MarketBeat users.
ProSomnus has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, indicating that its stock price is 223% less volatile than the S&P 500.
ProSomnus has a net margin of -87.14% compared to ProSomnus' net margin of -776.76%. Obalon Therapeutics' return on equity of 0.00% beat ProSomnus' return on equity.
70.0% of ProSomnus shares are held by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are held by institutional investors. 7.7% of ProSomnus shares are held by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Obalon Therapeutics' average media sentiment score of 0.00 equaled ProSomnus'average media sentiment score.
Summary
ProSomnus beats Obalon Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Obalon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OBLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Obalon Therapeutics Competitors List
Related Companies and Tools
